var data={"title":"Epidemiology and pathogenesis of systemic lupus erythematosus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Epidemiology and pathogenesis of systemic lupus erythematosus</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Peter H Schur, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Bevra H Hahn, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">David S Pisetsky, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/contributors\" class=\"contributor contributor_credentials\">Monica Ramirez Curtis, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reported prevalence of systemic lupus erythematosus (SLE) in the United States is 20 to 150 cases per 100,000 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/1-3\" class=\"abstract_t\">1-3</a>]. In women, prevalence rates vary from 164 (white) to 406 (African American) per 100,000 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/2\" class=\"abstract_t\">2</a>]. Due to improved detection of mild disease, the incidence nearly tripled in the last 40 years of the 20<sup>th</sup> century [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/4\" class=\"abstract_t\">4</a>]. Estimated incidence rates are 1 to 25 per 100,000 in North America, South America, Europe, and Asia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/3,5-7\" class=\"abstract_t\">3,5-7</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h2\">Geographic and racial distribution</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both geography and race affect the prevalence of SLE and the frequency and severity of clinical and laboratory manifestations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The disease appears to be more common in urban than rural areas [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/2,8\" class=\"abstract_t\">2,8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In the United States, the prevalence of SLE is higher among Asians, African Americans, African Caribbeans, and Hispanic Americans compared with Caucasians [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/3,5,6,8\" class=\"abstract_t\">3,5,6,8</a>]. In European countries, the prevalence of SLE is also higher among people of Asian and African descent [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/3\" class=\"abstract_t\">3</a>]. By comparison, SLE occurs infrequently in Africa [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/3,9\" class=\"abstract_t\">3,9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In New Zealand, the prevalence and mortality of SLE are higher in Polynesians than Caucasians [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Photosensitivity and discoid skin lesions may be more frequent clinical manifestations in patients with Northern European ancestry than those with Southern European ancestry; the former group is, however, less likely to have anticardiolipin and anti-double-stranded DNA (anti-dsDNA) antibodies [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/11\" class=\"abstract_t\">11</a>].</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Gender</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The increased frequency of SLE among women has been attributed in part to an estrogen hormonal effect [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/12,13\" class=\"abstract_t\">12,13</a>] (see <a href=\"#H8\" class=\"local\">'Hormonal factors'</a> below). An estrogen effect is suggested by a number of observations, including the female-to-male ratio of SLE in different age groups:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In children, in whom sex hormonal effects are presumably minimal, the female-to-male ratio is 3:1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In adults, especially in women of childbearing years, the ratio ranges from 7:1 to 15:1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/2,14\" class=\"abstract_t\">2,14</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In &quot;older&quot; individuals, especially post-menopausal women, the ratio is approximately 8:1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/14\" class=\"abstract_t\">14</a>].</p><p/><p>Factors related to the X chromosome may also be important in predisposing women to SLE. At least three predisposing gene variants are located on X chromosomes (IRAK1, MECP2, TLR7) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/15\" class=\"abstract_t\">15</a>]. There is also evidence for a gene dose effect, since the prevalence of XXY (Klinefelter's syndrome) is increased 14-fold in men with SLE when compared with the general population of men, whereas XO (Turner's syndrome) is underrepresented in women with SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/16\" class=\"abstract_t\">16</a>].</p><p>Other possibilities for female predisposition include: X-inactivation, imprinting, X or Y chromosome genetic modulators, differential methylation of DNA and acetylation of histones bound to DNA, intrauterine influences, chronobiologic differences, pregnancy, microchimerism following pregnancies, and menstruation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/17-19\" class=\"abstract_t\">17-19</a>].</p><p>However, it is important to note that SLE that occurs in men is slightly different clinically from that in women, and men tend to have worse outcomes [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/20\" class=\"abstract_t\">20</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Age at onset</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sixty-five percent of patients with SLE have disease onset between the ages of 16 and 55 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/21\" class=\"abstract_t\">21</a>]. Of the remaining cases, 20 percent present before age 16 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/22\" class=\"abstract_t\">22</a>] and 15 percent after age 55 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/23\" class=\"abstract_t\">23</a>]. Median ages at diagnosis for white females range from 37 to 50 years, in white males from 50 to 59, in black females from 15 to 44 and in black males from 45 to 64 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Factors affecting disease outcome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Different epidemiologic subgroups (eg, <span class=\"nowrap\">race/ethnicity,</span> gender, and age of onset) tend to have varying degrees of disease activity and may thus affect disease outcome:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>African Americans and Mexican Hispanics in the United States have a poorer renal prognosis than Caucasians, a finding not entirely independent of socioeconomic status [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/24\" class=\"abstract_t\">24</a>]. African Americans are more likely to have anti-Sm, anti-RNP, discoid skin lesions, proteinuria, psychosis, and serositis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/24-26\" class=\"abstract_t\">24-26</a>]. African Americans and Latin Americans with lupus nephritis are also less likely to respond to <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> treatment than Caucasians [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/27\" class=\"abstract_t\">27</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical status is poorer in those with less education [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/24,28\" class=\"abstract_t\">24,28</a>]; this effect may reflect poor compliance [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/29\" class=\"abstract_t\">29</a>]. Clinical status is also poorer in those with lower socioeconomic status and with inadequate access to medical care [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/30\" class=\"abstract_t\">30</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The extent and degree of activity of SLE varies in different countries and in different ethnic groups [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/30-32\" class=\"abstract_t\">30-32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Men with lupus tend to have higher frequencies of renal disease, skin manifestations, cytopenias, serositis, neurologic involvement, thrombosis, cardiovascular disease, hypertension, and vasculitis than women [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/33\" class=\"abstract_t\">33</a>]. By contrast, Raynaud phenomenon, photosensitivity, and mucosal ulceration are less frequent manifestations in men than women. Most, but not all studies suggest that men have a higher one-year mortality rate [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/33-38\" class=\"abstract_t\">33-38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SLE in children tends to be symptomatically more severe than in adults, with a high incidence of malar rashes, nephritis, pericarditis, hepatosplenomegaly, and hematologic abnormalities [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/22,34\" class=\"abstract_t\">22,34</a>].</p><p/><p>Lupus tends to be milder in older adults, who often have a presentation more similar to that of drug-induced lupus. Clinical features of lupus in older patients include the following [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/34,39-41\" class=\"abstract_t\">34,39-41</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A lower ratio of affected women to men than for younger patients</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lower incidence of malar rash, photosensitivity, purpura, alopecia, Raynaud phenomenon, renal, central nervous system, and hematologic involvement</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lower prevalence of anti-La, anti-Sm, and anti-RNP antibodies and of hypocomplementemia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Greater prevalence of sicca symptoms, serositis, pulmonary involvement, and musculoskeletal manifestations</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Greater prevalence of rheumatoid factor</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The etiology of systemic lupus erythematosus (SLE) remains unknown and is clearly multifactorial. Many observations suggest a role for genetic, hormonal, immunologic, and environmental factors.</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Genetic factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following observations are compatible with a genetic role in the pathogenesis of SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/42-44\" class=\"abstract_t\">42-44</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is a high concordance rate (14 to 57 percent) of SLE in monozygotic twins [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/45,46\" class=\"abstract_t\">45,46</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A large population-based study from Taiwan with over 23 million participants found that first-degree relatives have a 17-fold increased risk of SLE compared with the general population [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/47\" class=\"abstract_t\">47</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The sibling risk for developing SLE is 29-fold higher than in the general population [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/48\" class=\"abstract_t\">48</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Twenty-seven percent of 195 children of mothers with lupus had a positive test for antinuclear antibodies (ANAs) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/49\" class=\"abstract_t\">49</a>].</p><p/><p>Genome-wide association studies (GWAS) have identified approximately 50 gene loci with polymorphisms (or, rarely, mutations or copy numbers) that predispose to SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/15,50-53\" class=\"abstract_t\">15,50-53</a>]. However, this genetic information accounts for only 18 percent of susceptibility to SLE, suggesting a large component of environmental or epigenetic influences. The gene polymorphisms that increase risk for SLE can be understood best if SLE is considered to be caused initially by pathogenic autoantibodies and immune complexes (IC) that consist of nucleic acid derived from dead and dying cells and antibodies that bind to these nucleic acids <span class=\"nowrap\">and/or</span> proteins bound to them. The production of the aforementioned autoantibodies and IC depend upon:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Activation of innate immunity &ndash; Important in such activation are interactions between toll-like receptor 7 (TLR7) and ribonucleic acid (RNA) and TLR9 (TLR9) and deoxyribonucleic acid (DNA).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Activation of adaptive immunity &ndash; T and B cells may be activated by interaction with self-antigens on or released by apoptotic cells.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenic role for these autoantibodies and IC have been demonstrated in lupus nephritis, in some forms of lupus dermatitis, in autoimmune cytopenias, and in fetal loss associated with antiphospholipid antibodies but not in every clinical manifestation of SLE.</p><p/><p>Genetic factors that confer the highest hazard ratios (HR) of 5 to 25 are deficiencies of the complement components C1q (required to clear apoptotic cells), C4A and B, C2, or the presence of a mutated <em>TREX1</em> gene (encodes the three prime repair endonuclease1 enzyme that degrades DNA). Each of these is relatively rare in the population. A heterozygous mutation in the <em>TREX1</em> gene has been associated with familial chilblain lupus [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/54\" class=\"abstract_t\">54</a>]. Similarly, polymorphism in some DNA repair genes (<em>ATG5</em>, <em>TREX1</em>, <em>DNASE1</em>) predispose to SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/15\" class=\"abstract_t\">15</a>].</p><p>The most common genetic predisposition is found at the major histocompatibility (MHC) locus. The MHC contains genes for antigen-presenting molecules (class I human leukocyte antigens [HLA-A, -B, and -C] and class II HLA molecules [HLA-DR, -DQ, and DP]) (see <a href=\"topic.htm?path=human-leukocyte-antigens-hla-a-roadmap\" class=\"medical medical_review\">&quot;Human leukocyte antigens (HLA): A roadmap&quot;</a>). The MHC also contains genes for some complement components, cytokines, and heat shock protein.</p><p>Predisposing loci, which include HLA-DR2 and HLA-DR3, are associated with HR of approximately 2, but the region is complex and involves multiple genes across the entire 120-gene region in multiple ethnic groups [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/55,56\" class=\"abstract_t\">55,56</a>]. Within HLA-DRB1 loci, HLA-DRB1*0301 and HLA-DRB1*1501 predispose to SLE whereas HLA-DRB1*1401 reduces risk. The HR for predisposing <span class=\"nowrap\">HLA-DR/DQ</span> is approximately 2.4 and is increased in patients homozygous for predisposing alleles, indicating a gene dose effect. HR for other genes varies from 1.2 to 2.3, with additional reports of significant, but relatively low HR-conferring, genes occurring at a rapid pace.</p><p>Other genes with predisposing variants involve some associated with innate immunity (<em>IRF5</em>, <em>STAT4</em>, <em>IRAK1</em>, <em>TNFAIP3</em>, <em>SPP1</em>, <em>TLR7</em>), most of which are associated with interferon (IFN)-alpha pathways. Close to half of the genetic susceptibility loci associated with SLE involve type 1 IFN production or downstream signaling [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/57\" class=\"abstract_t\">57</a>], and several of these genes are hypomethylated [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/58\" class=\"abstract_t\">58</a>]. Overexpression of IFN-alpha-induced genes is found in the peripheral blood of 60 to 80 percent of patients with SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/59,60\" class=\"abstract_t\">59,60</a>]. Some of the lupus-predisposing polymorphisms in <em>STAT4</em>, <em>PTPN22</em>, and <em>IRF5</em> are associated with high levels of or increased sensitivity to IFN-alpha [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/59,61,62\" class=\"abstract_t\">59,61,62</a>]. Most genetic influences are complex and depend on gene polymorphisms and gene expression, which is influenced by epigenetic modification, short-interfering (si)RNAs, and gene copies. As an example, expression of TLR7 protein depends upon genetic polymorphisms, their interaction with at least one microRNA (miRNA), and the number of gene copies [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/63,64\" class=\"abstract_t\">63,64</a>].</p><p>Still other predisposing genes involve lymphocyte signaling (<em>PTPN22</em>, <em>OX40L</em>, <em>PD-1</em>, <em>BANK-1</em>, <em>LYN</em>, <em>BLK</em>), each of which plays a role in activation or suppression of T- or B-cell activation or survival. Other genes influence clearance of immune complexes (complement components C1q, C4, and C2 mentioned above; FcgammaRIIA; RIIIB; CRP; and integrin alpha M [ITGAM]). In some cases, the genetic component is found in promoter regions (eg, interleukin [IL]-10) or is conferred by a variation in gene copy number rather than by different alleles (eg, FcgammaR3 and complement C4) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/64-67\" class=\"abstract_t\">64-67</a>].</p><p>In summary, except for the rare <em>TREX1</em> mutation or deficiencies of early components of complement, there is no single gene polymorphism that creates high risk for SLE. Thus, a combination of susceptibility genes, or the presence of susceptibility genes plus the absence of protective genes (such as <em>TLR5</em> polymorphism or loss-of-function <em>PTPN22</em> variant), is required to &quot;achieve&quot; enough genetic susceptibility to permit disease development [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/68,69\" class=\"abstract_t\">68,69</a>], with high likelihood that environmental triggers or epigenetic changes are also required [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/70,71\" class=\"abstract_t\">70,71</a>].</p><p>In addition to genome-encoded susceptibility genes, epigenetic modifications are important in pathogenesis of SLE. These include hypomethylation of DNA [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/58,72\" class=\"abstract_t\">58,72</a>], which influences transcription into protein. The hypomethylation affects specific genes and variation in acetylation of histones, both of which influence transcription into protein. The influence of miRNA, some of which control epigenetic modifications, on transcription of several SLE-predisposing genes has been identified [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/72,73\" class=\"abstract_t\">72,73</a>]. There may be as many as 1850 human transcription factors (TF). These interact with specific DNA-binding elements in the promoters of certain genes to promote transcriptional initiation. Defects in TF regulation play critical roles in the immune system. In SLE, both upregulator and downregulator TFs have been identified [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/74\" class=\"abstract_t\">74</a>]. Other abnormalities in SLE patients have also been described, including defects in gene transcription, post-transcriptional regulation, messenger RNA (mRNA) editing, alternative splicing, and protein modification [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/74\" class=\"abstract_t\">74</a>].</p><p>In understanding the role of genes and their modifications in SLE, it is important to remember that many of the SLE genetic studies have lumped all patients with SLE together. However, several have studied immunologic and clinical subsets [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/75-77\" class=\"abstract_t\">75-77</a>]. There are known associations between certain gene polymorphisms and nephritis (including genes that modulate the renal disease but do not predispose to SLE per se) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/78\" class=\"abstract_t\">78</a>], as well as genes associated with arthritis, cytopenias, dermatitis, anti-DNA, <span class=\"nowrap\">anti-Ro/La,</span> and anti-Sm. An additional complexity of understanding mechanisms by which genes modulate disease is variability of gene and protein expression depending upon whether the source is whole blood, isolated peripheral blood mononuclear cells, neutrophils, <span class=\"nowrap\">monocyte/macrophages,</span> dendritic cells, or B or T cells (including different subsets of these cell types) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/79\" class=\"abstract_t\">79</a>].</p><p>As examples of associations of genes with clinical and immunologic phenotypes, we list some of the single-nucleotide polymorphisms (SNPs) in SLE risk genes predisposed to particular clinical subsets of SLE.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The SNP in the third intron of <em>STAT4</em> (which predisposes to both rheumatoid arthritis and SLE in several ethnic groups) increases risk for anti-DNA antibodies, nephritis, and the antiphospholipid syndrome [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/80-83\" class=\"abstract_t\">80-83</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>SNPs associated with <em>LYN</em> decrease risk for SLE susceptibility and for hematologic manifestations in European American cohorts [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/84\" class=\"abstract_t\">84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A <em>CRP-A</em> allele is associated with SLE nephritis but is inversely correlated with arthritis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/85\" class=\"abstract_t\">85</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The polymorphism of FcgammaRIIa associated with low binding of immune complexes predisposes to lupus nephritis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/85-87\" class=\"abstract_t\">85-87</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A coding variant of the <em>ITGAM</em> gene is associated with the development of renal disease, discoid rash, and &ldquo;immunological manifestations&rdquo; in patients with SLE with European ancestry. The <em>R77H</em> variant of <em>ITGAM</em> has been proposed to decrease immune complex clearance [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/88,89\" class=\"abstract_t\">88,89</a>].</p><p/><p>Stratification by disease phenotypes may be of benefit in genetic analyses of molecular pathogenesis. A GWAS of SLE patients stratified by ancestry and extremes of phenotype in serology and serum IFN-alpha, and using a multi-step screening approach, identified several loci of particular interest; each of these demonstrated a strong association with increased serum IFN-alpha and a particular serologic profile [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/90\" class=\"abstract_t\">90</a>]. These included <em>LRRC20</em> and <em>PPM1H</em> (both with anti-La), <em>LPAR1</em> (with anti-Ro and &ndash;Sm), <em>ANKS1A</em> (with anti-Ro and anti-double-stranded DNA [anti-dsDNA]), and <em>VSIG2</em> (with anti-RNP, but lacking anti-Sm). Additionally, SNPs in both <em>PTPRM</em> and <em>LRRC20</em> were associated with increased serum IFN-alpha independent of serologic profile. The findings demonstrate heterogeneity in SLE molecular pathogenesis and indicate the potential importance of these variants for sub-phenotypes of SLE, because none of the SNPs were strongly associated with SLE in case-control analysis.</p><p>Genes on different chromosomes are also associated with clinical subsets such as nephritis (2q34), hemolytic anemia (11q14), discoid lupus and thrombocytopenia (11p13), and vitiligo (17p12); to production of certain autoantibodies (eg, anti-dsDNA [19p13.2]); or to increased risk for end-stage renal disease [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Hormonal factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The immunoregulatory function of estradiol, testosterone, progesterone, dehydroepiandrosterone (DHEA), and pituitary hormones, including prolactin, has supported the hypothesis that they modulate the incidence and severity of SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/13,14,91,92\" class=\"abstract_t\">13,14,91,92</a>]. In support of the potential role of estrogens in predisposing to SLE, the Nurse's Health study showed that women with early menarche, or treated with estrogen-containing regimens such as oral contraceptives or postmenopausal hormone replacement therapies, have a significantly increased risk for SLE (HR of 1.5 to 2.1 ) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/13,93\" class=\"abstract_t\">13,93</a>]. However, others have either noted no effect of varied hormone levels, or treatment with hormones, on inducing lupus or flares thereof, or equivocal effects [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/91,93-96\" class=\"abstract_t\">91,93-96</a>]. On the other hand, estrogen can stimulate the type 1 IFN pathway, while progesterone may inhibit it, suggesting that a balance between the two hormones may be important [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/97\" class=\"abstract_t\">97</a>].</p><p>The pathogenic role of hormones in SLE may be related to their effects on immune responsiveness. Estrogen stimulates thymocytes, CD8+ and CD4+ T cells, B cells, macrophages, the release of certain cytokines (eg, IL-1), and the expression of both HLA and endothelial cell adhesion molecules (VCAM, ICAM) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/98,99\" class=\"abstract_t\">98,99</a>]. Estrogen also causes increased macrophage proto-oncogene expression and enhanced adhesion of peripheral mononuclear cells to endothelium [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/98\" class=\"abstract_t\">98</a>]. Another potentially important effect of estradiol may be its ability to reduce apoptosis in self-reactive B cells, thus promoting selective maturation of autoreactive B cells with high affinity for anti-DNA [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/100\" class=\"abstract_t\">100</a>]. Consequently, women are more predisposed to make autoantibodies that eventually lead to clinically apparent SLE. By comparison, androgens tend to be immunosuppressive [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/101\" class=\"abstract_t\">101</a>]. Serum levels of DHEA, an intermediate compound in testosterone synthesis, are low in nearly all patients with SLE. Estrogen upregulates IL-21 expression in CD4+ T cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/102\" class=\"abstract_t\">102</a>].</p><p>Progesterone and prolactin also affect immune activity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/103,104\" class=\"abstract_t\">103,104</a>]. Progesterone downregulates T-cell proliferation and increases the number of CD8 cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/103\" class=\"abstract_t\">103</a>], while lupus flares have been associated with hyperprolactinemia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/105\" class=\"abstract_t\">105</a>]. In addition, both progesterone and high levels of estrogen promote a Th2 response, which favors autoantibody production [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Thyroid hormone may influence SLE, or vice versa. There is an increased incidence of thyroid disease in patients with SLE. In one study of 41 patients with SLE, for example, the incidence of both antithyroid antibodies (51 versus 27 percent) and elevated serum thyroid-stimulating hormone (TSH) levels (24 versus 12 percent) were higher than in controls [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/106\" class=\"abstract_t\">106</a>].</p><p>Abnormalities of the hypothalamus-pituitary-adrenal axis may also exist among those with SLE. SLE patients appear to have an abnormal reaction to stress characterized by a heightened response to human corticotropin-releasing hormone (hCRH) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/107\" class=\"abstract_t\">107</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Immune abnormalities</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are numerous immune defects in patients with SLE. However, the etiology of these abnormalities remains unclear; we do not know which defects are primary and which are secondarily induced. In certain cases, these immune defects are episodic, and some correlate with disease activity.</p><p>SLE is primarily a disease with abnormalities in immune regulation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/108-110\" class=\"abstract_t\">108-110</a>]. These abnormalities are thought to be secondary to a loss of self-tolerance; thus, affected patients (either before or during disease evolution) are no longer totally tolerant to all of their self-antigens and consequently develop an autoimmune response [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111,112\" class=\"abstract_t\">111,112</a>].</p><p>The mediators of SLE are autoantibodies and the immune complexes they form with antigens; the autoantibodies are usually present for years before the first symptom of disease appears [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/113\" class=\"abstract_t\">113</a>]. Self-antigens that are recognized are presented primarily on cell surfaces, particularly by cells that are activated or undergoing apoptosis (or NETosis in the case of neutrophils), where intracellular antigens access cell surfaces where they can be recognized by the immune system [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/114,115\" class=\"abstract_t\">114,115</a>].</p><p>Phagocytosis and clearing of immune complexes, of apoptotic cells, and of necrotic cell-derived material are defective in SLE, allowing persistence of antigen and immune complexes [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/115,116\" class=\"abstract_t\">115,116</a>]. B <span class=\"nowrap\">cells/plasma</span> cells that make autoantibodies are more persistently activated and driven to maturation by B-cell activating factor (BAFF, also known as B lymphocyte stimulator, BLyS) and by persistently activated T helper cells making B-supporting cytokines such as IL-6 and IL-10. BAFF (BLyS), serum levels of which are elevated in many patients with SLE, is essential for maturation and survival of post-bone marrow transitional and immature B cells into autoantibody-secreting plasmablasts and memory B cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/117\" class=\"abstract_t\">117</a>]. Both short- and long-lived plasma cells make anti-DNA; targeting both might be desirable to suppress SLE. In untreated SLE, the increased autoantibody production and persistence is not downregulated appropriately by anti-idiotypic antibodies or regulatory immune cells (CD4+CD25hi-Foxp3+ Treg cells, Foxp3+CD8+ Tregs, T17regs, Bregs, myeloid regulatory cells).</p><p>As mentioned earlier, some <span class=\"nowrap\">antibody/antigen</span> complexes, particularly those containing DNA or <span class=\"nowrap\">RNA/proteins,</span> activate the innate immune system via <em>TLR9</em> or <em>TLR7</em>, respectively. Thus, dendritic cells are activated and release type 1 IFNs and tumor necrosis factor (TNF)-alpha; T cells release IFN-gamma, IL-6, and IL-10; while natural killer (NK) and T cells fail to release adequate immunosuppressive quantities of transforming growth factor (TGF)-beta. These cytokine patterns favor continued autoantibody formation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/118\" class=\"abstract_t\">118</a>].</p><p>The innate immune system may also be activated by infections (bacterial or RNA- or DNA-containing viruses). Thus both innate and adaptive immunity conspire to continually produce autoantibodies; that response is regulated for a few years; if regulation fails, clinical disease results.</p><p>The following are some of the immune abnormalities that have been described in SLE which relate to the vicious cycle described in the preceding discussion:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated circulating levels of IFN-alpha and increased expression of IFN-alpha-inducible RNA transcripts by mononuclear cells, especially in patients with active disease, occur in most SLE patients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/119-126\" class=\"abstract_t\">119-126</a>]. The elevated levels of IFN-alpha and increased expression of IFN-alpha-inducible transcripts may be due in part to the presence of predisposing genetic factors affecting IFN expression [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/127\" class=\"abstract_t\">127</a>]. A similar increase in IFN-alpha-inducible transcripts occurs in synovial tissue [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/128\" class=\"abstract_t\">128</a>]. Patients with the SLE risk-enhancing <em>PTPN22</em> <em>C1858T</em> allele are more likely to have elevated circulating INF-alpha, which may contribute to inflammation [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/62\" class=\"abstract_t\">62</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An increase in circulating plasma cells and in a subset of memory B cells is associated with disease activity in SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/129,130\" class=\"abstract_t\">129,130</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A decrease in cytotoxic T cells and in functions of suppressor T cells (which would normally downregulate immune responses) occurs in most patients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/131\" class=\"abstract_t\">131</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Impaired generation of polyclonal T-cell cytolytic activity occurs in some [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/132\" class=\"abstract_t\">132</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An increase in helper (CD4+) T cells and helper function by both CD4+ and CD8+ T cells is characteristic [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/133-135\" class=\"abstract_t\">133-135</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polyclonal activation of B cells and abnormal B-cell receptor signaling [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/133,136\" class=\"abstract_t\">133,136</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple signaling abnormalities of T and B lymphocytes, including cellular hyperactivity and hyperresponsiveness, which may be partially due to genetically or epigenetically determined defects occur in most patients [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/137-141\" class=\"abstract_t\">137-141</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Defects in B-cell tolerance, perhaps related to defects in apoptosis <span class=\"nowrap\">and/or</span> complement deficiency, lead to prolonged lives of B cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/98,142-144\" class=\"abstract_t\">98,142-144</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased BAFF (BLyS) expression may promote autoimmunity. B cells have three receptors for BAFF: BAFFR, B-cell maturation antigen (BCMA), and transmembrane activator and calcium-modulator and cyclophilin ligand interactor (TACI) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/117,145\" class=\"abstract_t\">117,145</a>]. BAFF, which is produced primarily by neutrophils and <span class=\"nowrap\">monocyte/macrophages,</span> increases survival of B2 cells after their transitional T1 phase (which means the B cells have survived several deleting and anergizing tolerance mechanisms), as well as survival of resting memory B cells and plasmablasts. Stimulation by BAFF is particularly important for the survival of T-dependent B cells, the source of many autoantibodies. (See <a href=\"topic.htm?path=normal-b-and-t-lymphocyte-development\" class=\"medical medical_review\">&quot;Normal B and T lymphocyte development&quot;</a>.)</p><p/><p class=\"bulletIndent1\">Increased BAFF (BLyS) production is promoted by increased TLR activation and increased type 1 and 2 IFNs; in turn, BAFF promotes increased TLR activation. Thus, BAFF can contribute to sustained autoantibody production by several mechanisms. Clinical trials have demonstrated that <a href=\"topic.htm?path=belimumab-drug-information\" class=\"drug drug_general\">belimumab</a>, a monoclonal antibody to BAFF, is beneficial for the treatment of patients with SLE, for whom its use has been approved by the US Food and Drug Administration (FDA) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/117,145-147\" class=\"abstract_t\">117,145-147</a>]. A proliferation-inducing ligand (APRIL), made primarily by dendritic cells, binds TACI and an additional B-cell receptor, BCMA. In some conditions, APRIL promotes B-cell survival and in others can provide a negative signal.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dysfunctional signaling in T and B cells, which is manifested by increased calcium responses to antigen stimulation; hyperphosphorylation of cytosolic protein substrates; decreased nuclear factor kB; and abnormal voltage-gated potassium (Kv1.3) channels are implicated in facilitating excessive calcium entry into T cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/148,149\" class=\"abstract_t\">148,149</a>]. These changes probably account for the decreased IL-2 production of lupus T cells, which might contribute to inability to generate adequate numbers of functioning regulatory T cells.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased fetal microchimerism [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/150\" class=\"abstract_t\">150</a>] providing &quot;foreign&quot; antigens to the immune system.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased levels of microparticles (MPs), which are small, membrane-bound vesicles that contain DNA, RNA, nuclear proteins, cell-adhesion molecules, growth factors, and cytokines. These MPs are shed from cells during apoptosis or activation. MPs can drive inflammation and autoimmunity, including through immune complexes [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/151\" class=\"abstract_t\">151</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Elevated levels of circulating TNF-alpha correlate with active disease, and TNF is expressed in renal tissue in lupus nephritis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/152\" class=\"abstract_t\">152</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with SLE treated with antimalarials, a genotype associated with low TNF and high IL-10 levels correlated with higher serum concentrations of IFN-alpha, while those with high TNF-alpha and low IL-10 levels had increased numbers of regulatory T cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/152\" class=\"abstract_t\">152</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormally high levels of erythrocyte C4-derived activation fragments (C4d) and low levels of erythrocyte complement receptor (CR1) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/153\" class=\"abstract_t\">153</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormal <em>TLR7</em> signaling in response to RNA and <em>TLR9</em> signaling in response to DNA [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/154,155\" class=\"abstract_t\">154,155</a>] and increased expression of <em>TLR9</em> on peripheral blood B cells,plasma cells, and dendritic cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/154,156-160\" class=\"abstract_t\">154,156-160</a>]. This means that B cells can be activated to secrete autoantibody by the innate immune system, independent of T-cell help.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased numbers of circulating neutrophils undergoing NETosis, a form of apoptosis specific for neutrophils, releases DNA bound to protein in protein nets, which stimulates anti-DNA and IFN-alpha production [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/161,162\" class=\"abstract_t\">161,162</a>], probably involving <em>TLR9</em>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Stimulation of <em>TLR7</em> or <em>TLR9</em> reduces the immunosuppressive activity of glucocorticoids, suggesting that nucleic acid containing immune complexes that induce TLR signaling may limit effectiveness of glucocorticoids and may account for the high doses required for therapy [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/163\" class=\"abstract_t\">163</a>]. Correspondingly, blocking stimulation of <em>TLR7</em> or <em>TLR9</em> may be useful therapeutically and restore sensitivity to glucocorticoids.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Higher expression of <em>TLR9</em> on B cells as well as low CH50 levels associated with increased SLE Disease Activity Index (SLEDAI) scores [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/158\" class=\"abstract_t\">158</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased serum levels of HMGB1 (high mobility group box chromosomal protein 1) in patients with SLE is associated with disease activity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/164,165\" class=\"abstract_t\">164,165</a>]. Whether this is specific for SLE is as yet not clear; antibodies to HMG have been noted in patients with juvenile idiopathic arthritis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/166\" class=\"abstract_t\">166</a>]. (See <a href=\"topic.htm?path=clinical-significance-of-antinuclear-antibody-staining-patterns-and-associated-autoantibodies\" class=\"medical medical_review\">&quot;Clinical significance of antinuclear antibody staining patterns and associated autoantibodies&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disrupted T effector cell differentiation involving the <span class=\"nowrap\">Wnt/beta-catenin</span> pathway contribute to immune dysfunction in SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/167\" class=\"abstract_t\">167</a>].</p><p/><p>These changes promote the production of antinuclear antibodies (ANAs, see below). In addition, certain strains of mice (eg, those with the lpr, also known as <span class=\"nowrap\">Fas-/Fas-</span> mutation) have a genetic defect in apoptosis, resulting in abnormal programmed cell death that allows the development of autoreactivity and the dramatic increase in an aberrant lymphoid population. Humans with a comparable mutation (ie, autoimmune lymphoproliferative syndrome) display abnormal lymphoproliferation in association with cytopenias and autoimmunity. In humans with lupus, dysregulation of apoptosis has been demonstrated among different cell types, particularly T lymphocytes and the <span class=\"nowrap\">Fas/Fas</span> ligand pathway [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/137\" class=\"abstract_t\">137</a>]; some SLE patients also have defective clearing of apoptotic cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/168\" class=\"abstract_t\">168</a>]. (See <a href=\"topic.htm?path=apoptosis-and-autoimmune-disease#H9\" class=\"medical medical_review\">&quot;Apoptosis and autoimmune disease&quot;, section on 'Autoimmune lymphoproliferative syndrome'</a>.)</p><p>C1q and antiphospholipid antibodies enhance opsonization and clearance [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/169-172\" class=\"abstract_t\">169-172</a>]; thus, depressed levels of C1q and C4 may impair phagocytosis and delay clearance [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/173,174\" class=\"abstract_t\">173,174</a>]. The act of phagocytosis results in a stimulation of the immune response to autoantigens derived from the apoptotic cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/175,176\" class=\"abstract_t\">175,176</a>]. In addition, protein cleavage by caspases and granzyme B may promote the antigenicity of the contents of apoptotic cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/115\" class=\"abstract_t\">115</a>].</p><p>Cleavage of complement with production of breakdown products is characteristic of most patients with active SLE. In fact, hypocomplementemia (especially in addition to rising serum levels of anti-DNA) is a fairly good predictor of disease flare. Measurement of C4d (a breakdown product) bound to erythrocytes <span class=\"nowrap\">and/or</span> to B cells has been reported to distinguish SLE from similar diseases and perhaps to be useful in predicting flares [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/177\" class=\"abstract_t\">177</a>].</p><p>As noted above, <em>TLR7</em> and <em>TLR9</em> may play a role in promoting autoimmunity. <em>ATLR7</em> and <em>ATLR9</em> are involved in the IFN-alpha response [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/178\" class=\"abstract_t\">178</a>], and immune complexes containing <span class=\"nowrap\">DNA/autoantibody</span> activate dendritic cells through cooperation of <em>CD32</em> and <em>TLR9</em> [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/159\" class=\"abstract_t\">159</a>]; similarly, RNA-containing self-antigens can activate dendritic cells through <em>TLR7</em> [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/160\" class=\"abstract_t\">160</a>], both by innate immune stimulation via <em>TLR7</em> (recognizes RNA) and <em>TLR9</em> (recognizes DNA), which can directly stimulate B cells to make autoantibodies, and by T-cell stimulation of B cells via adaptive immunity as well as activating the INF-alpha response (see below). Antimalarial drugs (eg, <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>) used to treat some manifestations of SLE block <em>TLR7</em> and <em>TLR9</em> signaling.</p><p>These multiple defects cause a cascade of events that begins with abnormal cellular breakdown and ends with the production of autoantibodies. As cells break down abnormally, certain (especially nuclear and cryptic self peptides [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/179\" class=\"abstract_t\">179</a>]) antigens are processed (perhaps abnormally [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/180,181\" class=\"abstract_t\">180,181</a>]) into peptides by antigen-presenting cells such as macrophages, B lymphocytes, and dendritic cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111,182\" class=\"abstract_t\">111,182</a>]. Alternatively, microorganisms may be broken down within antigen-presenting cells into &quot;mimicry peptides&quot; that have sufficient structural similarity with immunodominant self peptides [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/183\" class=\"abstract_t\">183</a>].</p><p>With either mechanism, a peptide-MHC complex forms and stimulates the activation and clonal expansion of CD4+ autoreactive T cells [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/183\" class=\"abstract_t\">183</a>]. These cells, via contact plus release of cytokines (eg, IL-4, IL-6, and IL-10) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111,184\" class=\"abstract_t\">111,184</a>], cause autoreactive B cells to become activated, proliferate, and differentiate into antibody-producing cells that make an excess of antibodies to many nuclear antigens [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111,182\" class=\"abstract_t\">111,182</a>]. At the same time, activation of the innate immune system with release of IL-1, TNF-alpha, type 1 IFNs, BAFF (BLyS), and APRIL promotes inflammation and survival of autoreactive B cells. Thus, a specific immune profile develops that is characterized by the development of elevated levels of ANAs, especially to DNA, Sm, RNP, Ro, La, nucleosomes, and other nuclear antigens [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111,185-187\" class=\"abstract_t\">111,185-187</a>]. Several of these autoantibodies are important clinically. ANAs appear at some time during the course of disease in &gt;95 percent of patients with SLE, so its absence on multiple testings suggests SLE is not the correct diagnosis. Anti-dsDNA is associated with higher risks for nephritis; anticardiolipins are associated with higher risk for clotting and fetal loss. <span class=\"nowrap\">Anti-Ro/SSA</span> is associated with a chronic form of lupus dermatitis as well as with higher risk for neonatal lupus.</p><p>ANAs are made to antigens from active sites on molecules involved in essential cellular functions (such as RNA splicing) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/187\" class=\"abstract_t\">187</a>]. With continued pressure over time from self-antigens, the immune response switches, via somatic hypermutation, from low-affinity, highly cross-reactive immunoglobulin M (IgM) antibodies; to high-affinity IgG antibodies; and then finally to antibodies directed toward more limited epitopes on self-antigens [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/188\" class=\"abstract_t\">188</a>]. Idiotypes of antibodies may then stimulate autoreactive T cells to expand, thereby helping unique clones of B cells to expand [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/189\" class=\"abstract_t\">189</a>]. The final result is the production of more specific ANAs [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/190\" class=\"abstract_t\">190</a>], which may precede clinical manifestations by years [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/113,191\" class=\"abstract_t\">113,191</a>].</p><p>Not all autoantibodies cause disease. In fact, all normal individuals make autoantibodies, although in small quantities. The variability in clinical disease that exists among different patients may therefore reflect the variability in the quality and quantity of the immune response, including regulatory networks.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Environmental factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The environment probably has a role in the etiology of SLE via its effects on the immune system.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viruses, for example, may stimulate antigen-specific cells in the immune network [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111,192,193\" class=\"abstract_t\">111,192,193</a>]. In addition, trypanosomiasis or mycobacterial or Epstein-Barr virus (EBV) infections may induce anti-DNA antibodies or even lupus-like symptoms, and lupus flares may follow bacterial infections (perhaps related to bacterial CpG motifs) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/148,194\" class=\"abstract_t\">148,194</a>]. Patients with SLE also have higher titers of antibodies to EBV, have increased circulating EBV viral loads, and make antibodies to retroviruses, including to protein regions homologous to nuclear antigens [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/195,196\" class=\"abstract_t\">195,196</a>]. In fact, studies in children with SLE suggest that EBV infection may be a triggering event resulting in clinical SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/195\" class=\"abstract_t\">195</a>]. Antibodies to these molecular mimicry molecules, and to endogenous retroviruses, may contribute to the development of autoimmunity [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/197,198\" class=\"abstract_t\">197,198</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ultraviolet (UV) light may stimulate keratinocytes to express more snRNPs on their cell surface [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/199,200\" class=\"abstract_t\">199,200</a>] and to secrete more IL-1, IL-3, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), and TNF-alpha, thereby stimulating B cells to make more antibodies. In addition to the local effects in skin, UV light may also increase the degree of systemic autoimmunity by interfering with antigen processing by and activation of macrophages. UV light decreases T-cell DNA methylation, which may lead to overexpression of lymphocyte function-associated antigen (LFA)-1 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/201\" class=\"abstract_t\">201</a>]. These T cells may then become autoreactive, resulting in autoantibody formation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Silica dust, found in cleaning powders, soil, pottery materials, cement, and cigarette smoke, may increase the risk of developing SLE, especially in African American women [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/12,202-207\" class=\"abstract_t\">12,202-207</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Allergies to medications, particularly to antibiotics, are reported more frequently in patients with newly diagnosed SLE than healthy controls [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/193\" class=\"abstract_t\">193</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is a slight, but significantly higher prevalence of lupus in pet dogs of patients with SLE (three cases among 59 pet dogs owned by 37 SLE patients, versus none among 187 dogs in non-SLE households) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/208\" class=\"abstract_t\">208</a>]. These observations suggest a possible common environmental factor for both human and dog systemic lupus.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is no apparent association between SLE and the use of hair dyes, occupational solvent exposure, the use of pesticides, or alcohol consumption [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/204,209\" class=\"abstract_t\">204,209</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A meta-analysis of studies of alcohol use and SLE risk concluded that moderate alcohol consumption had a protective effect [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/210\" class=\"abstract_t\">210</a>].</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PATHOGENESIS OF CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the exact etiology of systemic lupus erythematosus (SLE) remains obscure, it is clear that many of the clinical manifestations of SLE are mediated directly or indirectly by antibody formation and the creation of immune complexes (IC). As an example, IC deposition and subsequent complement activation in the kidney is responsible for much of the tissue damage of lupus nephritis (see <a href=\"topic.htm?path=diagnosis-and-classification-of-renal-disease-in-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Diagnosis and classification of renal disease in systemic lupus erythematosus&quot;</a>). IC have also been detected (by immunofluorescence <span class=\"nowrap\">and/or</span> electron microscopy) at the dermal-epidermal junction in both skin lesions and normal skin, as well as in the choroid plexus, the pericardium, and the pleural cavity.</p><p>The pathogenic potential of IC varies, depending on the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The characteristics of the antibody, such as its specificity, affinity, charge, and ability to activate complement or other mediators of inflammation. In the glomerulus, for example, different antibodies may bind to antigens at different sites in the glomerular capillary wall, leading to different histologic and clinical manifestations [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/211,212\" class=\"abstract_t\">211,212</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The nature of the antigen, such as its size and charge. Smaller cationic antigens, for example, are more able to cross the glomerular basement membrane and be deposited in the subepithelial region. The ensuing formation of IC should lead to membranous nephropathy rather than a proliferative glomerulonephritis. (See <a href=\"topic.htm?path=diagnosis-and-classification-of-renal-disease-in-systemic-lupus-erythematosus#H3\" class=\"medical medical_review\">&quot;Diagnosis and classification of renal disease in systemic lupus erythematosus&quot;, section on 'Pathogenesis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The ability of the IC to be solubilized by complement and bound to the complement receptor (CR1) on red blood cells (both systems may be defective in SLE).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The rate at which the IC are cleared by immunoglobulin Fc receptors on <span class=\"nowrap\">monocytes/macrophages</span> in the liver and spleen from the circulation may be genetically impaired in SLE [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/213\" class=\"abstract_t\">213</a>].</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Renal disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initiation of renal disease in SLE is likely due to the deposition or formation of immune complexes in the mesangium, subendothelial, or subepithelial spaces, with subsequent activation of complement.</p><p>IC in this disease consist of nuclear antigens (especially DNA), and high-affinity, complement-fixing immunoglobulin G (IgG) antinuclear antibodies (ANAs) [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/214\" class=\"abstract_t\">214</a>] (especially IgG1 and IgG3 [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/215\" class=\"abstract_t\">215</a>]), and antibodies to DNA [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/216\" class=\"abstract_t\">216</a>]. These complexes either form in the circulation, where they are poorly cleared [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/217\" class=\"abstract_t\">217</a>] or form in situ as free antibody binds to free antigen that has already deposited in the glomerulus or is an intrinsic glomerular antigen [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/218\" class=\"abstract_t\">218</a>]. Histones have high affinity for the glomerular basement membrane (GBM) and may facilitate IC deposition [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/219\" class=\"abstract_t\">219</a>]. Antibody reactivities in the serum that best correlate with active nephritis in human SLE are directed against <span class=\"nowrap\">DNA/chromatin</span> or <span class=\"nowrap\">laminin/myosin/vimentin/heparan</span> sulphate [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/220\" class=\"abstract_t\">220</a>], suggesting the importance of these reactivities to pathogenesis.</p><p>Elevated levels of anti-DNA antibodies commonly precede development of clinical lupus nephritis. This was illustrated in a study of serum samples collected from military recruits. Among those who developed SLE and renal disease, 92 percent had elevated levels of anti-double-stranded DNA (anti-dsDNA) antibodies present before diagnosis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/191\" class=\"abstract_t\">191</a>]. In addition, the combination of a rising level (titer) of anti-DNA and evidence of increased complement activation (eg, rising C3a), if detected, may allow preemptive treatment and avoid lupus flares [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/221\" class=\"abstract_t\">221</a>].</p><p>Once deposited in the mesangial or subendothelial aspect of the GBM, IC activate the complement system, thereby generating chemotactic factors that attract the infiltration of leukocytes and mononuclear cells. These cells phagocytose IC and release mediators (such as cytokines and activators of the clotting system) that perpetuate glomerular inflammation. With continuing IC deposition, chronic inflammation may ensue, ultimately leading to fibrinoid necrosis, scarring, and reduced renal function.</p><p>In addition, in situ antibody deposition occurring in the subepithelial space in lupus membranous nephropathy is not associated with cell or membrane damage. In this setting, complement is activated at a site that is separated from circulating inflammatory cells by the GBM [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/222\" class=\"abstract_t\">222</a>]. As a result, these patients develop epithelial cell injury and proteinuria but not active inflammation and glomerulonephritis.</p><p>An important consideration for likelihood of developing chronic renal disease, or end-stage renal disease, is the influence of immune deposition and complement activation on non-immune cells in the target tissue. When lupus nephritis begins, there is activation of endothelial cells, mesangial cells, podocytes, renal tubular epithelial cells, and tissue-fixed macrophages. It is possible that injury to any of these cells, or their combinations, activates pathways that can lead to glomerulosclerosis, interstitial nephritis, and interstitial fibrosis even if the initial offending immune attack subsides. The importance of the renal tissue-fixed macrophage to subsequent damage has been well-demonstrated in murine and human lupus nephritis [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/223,224\" class=\"abstract_t\">223,224</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Cell-surface antibodies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>SLE patients make antibodies to a number of cell-surface antigens. Antibodies to a 66-kDa membrane antigen have been implicated in lupus nephritis, vasculitis, and hypocomplementemia, as well as antibodies to a 55-kDa antigen in thrombocytopenia antibodies to a 18-kDa protein in thrombocytopenia [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/225\" class=\"abstract_t\">225</a>], and antibodies to neuronal cells in organic brain disease (see <a href=\"topic.htm?path=neurologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Neurologic manifestations of systemic lupus erythematosus&quot;</a>). Cell-surface antibodies also attach to red blood cells, lymphocytes, and platelets (see <a href=\"topic.htm?path=hematologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">&quot;Hematologic manifestations of systemic lupus erythematosus&quot;</a>). In addition, ANAs may interact with nuclear antigens expressed on cell surfaces, triggering cell injury and even death, either by activating complement <span class=\"nowrap\">and/or</span> by cell penetration [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/226\" class=\"abstract_t\">226</a>].</p><p>These complexes are cleared from the circulation, and may cause organ damage, through one of the following mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fc receptors on macrophages of the reticuloendothelial system</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complement-mediated cytotoxicity</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antibody-dependent cellular cytotoxicity (ADCC) resulting in hemolytic anemia, leukopenia, and thrombocytopenia</p><p/><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Antiphospholipid antibodies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with SLE may form antibodies to a phospholipid-beta-2-glycoprotein I complex. Beta-2-glycoprotein I normally has an anticoagulant effect that is diminished by blocking the antibody. This may explain why antiphospholipid antibodies are implicated in the etiology of the arterial and venous thromboses (causing strokes and thrombophlebitis), and in placental infarcts (causing miscarriages). Most antibodies that bind cardiolipin also bind beta-2-glycoprotein I; lupus anticoagulants are more likely to bind proteins required for thrombosis or clot lysis, such as thrombin. (See <a href=\"topic.htm?path=pathogenesis-of-antiphospholipid-syndrome#H11\" class=\"medical medical_review\">&quot;Pathogenesis of antiphospholipid syndrome&quot;, section on 'Pathogenesis'</a>.)</p><p>Antiphospholipid antibodies, like ANAs, may be present prior to the diagnosis of SLE. This was illustrated in a study of a cohort of 130 patients for whom stored serum samples that preceded the SLE diagnosis were available [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/227\" class=\"abstract_t\">227</a>]. The presence of anticardiolipin antibodies was noted in 24 patients who later developed SLE, and, in these patients, developed an average of three years prior to the diagnosis of SLE. Furthermore, the patients with anticardiolipin antibodies tended to develop more severe lupus than those without these antiphospholipid antibodies. Eleven patients with anticardiolipin antibodies developed thrombotic events prior to the diagnosis of SLE.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Skin lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Skin lesions are thought to be multifactorial in origin [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/228\" class=\"abstract_t\">228</a>] (see <a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">&quot;Overview of cutaneous lupus erythematosus&quot;</a>). In particular, exposure to ultraviolet (UV) light has a number of local effects in the skin:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It damages DNA. The patient can then make antibodies to DNA, IC form, complement is activated, and a local inflammatory response ensues.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It increases binding of anti-Ro, anti-La, and anti-RNP antibodies to UV-activated keratinocytes, which express those antigens in apoptotic blebs on the cell surface [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/229\" class=\"abstract_t\">229</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It alters cellular membrane phospholipid metabolism. Portions of cell membranes may be rearranged so the usually cytoplasmic-facing surfaces (and potentially antigenic molecules) are on the extracellular surface.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It increases interleukin (IL)-1 release from cutaneous keratinocytes and Langerhans cells.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It increases apoptosis of keratinocytes in patients with SLE and in healthy persons, but clearance of apoptotic cells by phagocytes is abnormal [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/230\" class=\"abstract_t\">230</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It induces inducible nitrogen oxide synthase (iNOS) expression and increased nitric oxide production in keratinocytes [<a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/231\" class=\"abstract_t\">231</a>].</p><p/><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=systemic-lupus-erythematosus-sle-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Systemic lupus erythematosus (SLE) (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H443498\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The prevalence of systemic lupus erythematosus (SLE) is 20 to 150 cases per 100,000; rates in women vary from 164 (Caucasian) to 406 (African American) per 100,000. The estimated incidence is 1 to 25 per 100,000 in North America, South America, Europe, and Asia. Both geography and race affect the prevalence of SLE and the frequency and severity of clinical and laboratory manifestations. The increased frequency of SLE among women has been attributed in part to an estrogen hormonal effect. (See <a href=\"#H1\" class=\"local\">'Epidemiology'</a> above and <a href=\"#H2\" class=\"local\">'Geographic and racial distribution'</a> above and <a href=\"#H3\" class=\"local\">'Gender'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Disease onset is between the ages of 16 and 55 in 65 percent of patients, but disease also occurs in both children and older individuals. Different epidemiologic subgroups, including those based upon <span class=\"nowrap\">race/ethnicity,</span> gender, and age of onset, tend to have varying degrees of disease activity and may differ in their prevalence of given clinical manifestations, which may affect disease outcome. (See <a href=\"#H4\" class=\"local\">'Age at onset'</a> above and <a href=\"#H5\" class=\"local\">'Factors affecting disease outcome'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The etiology of SLE remains unknown and is clearly multifactorial. Many observations suggest a role for genetic, hormonal, immunologic, and environmental factors. There is no single gene polymorphism that creates high risk for SLE, except for the rare <em>TREX1</em> mutation or deficiencies of early components of complement. A combination of susceptibility genes, or the presence of susceptibility genes plus the absence of protective genes, is required for sufficient genetic susceptibility to permit disease development, and it is likely that environmental or epigenetic changes play a major role. Additionally, some of the single-nucleotide polymorphisms (SNPs) in SLE risk genes predispose to particular clinical subsets of SLE. (See <a href=\"#H6\" class=\"local\">'Etiology'</a> above and <a href=\"#H7\" class=\"local\">'Genetic factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Substantial evidence of the immunoregulatory function of estradiol, testosterone, progesterone, dehydroepiandrosterone (DHEA), and pituitary hormones, including prolactin, has supported the hypothesis that these hormones modulate the incidence and severity of SLE. There are numerous immune defects in patients with SLE. However, the etiology of these abnormalities remains unclear; we do not know which defects are primary and which are secondarily induced. In certain cases, these immune defects are episodic, and some correlate with disease activity. The environment probably has a role in the etiology of SLE via its effects on epigenetic changes and the immune system. (See <a href=\"#H8\" class=\"local\">'Hormonal factors'</a> above and <a href=\"#H9\" class=\"local\">'Immune abnormalities'</a> above and <a href=\"#H10\" class=\"local\">'Environmental factors'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is clear that many of the clinical manifestations are mediated directly or indirectly by antibody formation and the creation of immune complexes (IC). Initiation of renal disease in SLE is likely due to the deposition or formation of IC in the mesangium, subendothelial, or subepithelial spaces, with subsequent activation of complement. Activated fixed tissue macrophages in the kidney also play a major role in tissue damage. SLE patients make antibodies to a number of cell-surface antigens, such as those to a phospholipid-beta-2 glycoprotein I complex; these antibodies are involved in thromboembolic events and obstetric complications. Skin lesions are thought to be multifactorial in origin; ultraviolet (UV) light has local effects in skin and may increase the degree of autoimmunity. (See <a href=\"#H11\" class=\"local\">'Pathogenesis of clinical manifestations'</a> above and <a href=\"#H12\" class=\"local\">'Renal disease'</a> above and <a href=\"#H13\" class=\"local\">'Cell-surface antibodies'</a> above and <a href=\"#H14\" class=\"local\">'Antiphospholipid antibodies'</a> above and <a href=\"#H15\" class=\"local\">'Skin lesions'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/1\" class=\"nounderline abstract_t\">Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/2\" class=\"nounderline abstract_t\">Chakravarty EF, Bush TM, Manzi S, et al. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56:2092.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/3\" class=\"nounderline abstract_t\">Pons-Estel GJ, Alarc&oacute;n GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39:257.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/4\" class=\"nounderline abstract_t\">Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum 1999; 42:46.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/5\" class=\"nounderline abstract_t\">Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006; 15:308.</a></li><li class=\"breakAll\">Rus V, Maury EE, Hochberg MC. The epidemiology of systemic lupus erythematosus. In: Dubois' Lupus Erythematosus, Wallace DJ, Hahn BH (Eds), Lippincott Williams and Wilkins, Philadelphia 2002.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/7\" class=\"nounderline abstract_t\">Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28:368.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/8\" class=\"nounderline abstract_t\">Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16:847.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/9\" class=\"nounderline abstract_t\">Symmons DP. Frequency of lupus in people of African origin. Lupus 1995; 4:176.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/10\" class=\"nounderline abstract_t\">Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Ann Rheum Dis 1983; 42:529.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/11\" class=\"nounderline abstract_t\">Chung SA, Tian C, Taylor KE, et al. European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis Rheum 2009; 60:2448.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/12\" class=\"nounderline abstract_t\">Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998; 41:1714.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/13\" class=\"nounderline abstract_t\">Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007; 56:1251.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/14\" class=\"nounderline abstract_t\">Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999; 11:352.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/15\" class=\"nounderline abstract_t\">Rullo OJ, Tsao BP. Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 2013; 72 Suppl 2:ii56.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/16\" class=\"nounderline abstract_t\">Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum 2008; 58:2511.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/17\" class=\"nounderline abstract_t\">Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. J Immunol 2006; 176:7143.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/18\" class=\"nounderline abstract_t\">Lockshin MD. Sex differences in autoimmune disease. Lupus 2006; 15:753.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/19\" class=\"nounderline abstract_t\">Hewagama A, Gorelik G, Patel D, et al. Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun 2013; 41:60.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/20\" class=\"nounderline abstract_t\">Gilbert EL, Ryan MJ. Estrogen in cardiovascular disease during systemic lupus erythematosus. Clin Ther 2014; 36:1901.</a></li><li class=\"breakAll\">Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.</li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/22\" class=\"nounderline abstract_t\">Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/23\" class=\"nounderline abstract_t\">Ballou SP, Khan MA, Kushner I. Clinical features of systemic lupus erythematosus: differences related to race and age of onset. Arthritis Rheum 1982; 25:55.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/24\" class=\"nounderline abstract_t\">Fern&aacute;ndez M, Alarc&oacute;n GS, Calvo-Al&eacute;n J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum 2007; 57:576.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/25\" class=\"nounderline abstract_t\">Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences. Arch Intern Med 1990; 150:849.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/26\" class=\"nounderline abstract_t\">Reveille JD, Bartolucci A, Alarc&oacute;n GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum 1990; 33:37.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/27\" class=\"nounderline abstract_t\">Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/28\" class=\"nounderline abstract_t\">Callahan LF, Pincus T. Associations between clinical status questionnaire scores and formal education level in persons with systemic lupus erythematosus. Arthritis Rheum 1990; 33:407.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/29\" class=\"nounderline abstract_t\">Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M. Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 1991; 91:345.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/30\" class=\"nounderline abstract_t\">Pons-Estel BA, Catoggio LJ, Cardiel MH, et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among &quot;Hispanics&quot;. Medicine (Baltimore) 2004; 83:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/31\" class=\"nounderline abstract_t\">Citera G, Wilson WA. Ethnic and geographic perspectives in SLE. Lupus 1993; 2:351.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/32\" class=\"nounderline abstract_t\">Johnson AE, Cavalcanti FS, Gordon C, et al. Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden. Lupus 1994; 3:501.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/33\" class=\"nounderline abstract_t\">Lu LJ, Wallace DJ, Ishimori ML, et al. Review: Male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010; 19:119.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/34\" class=\"nounderline abstract_t\">Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993; 72:113.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/35\" class=\"nounderline abstract_t\">Kaufman LD, Gomez-Reino JJ, Heinicke MH, Gorevic PD. Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 1989; 18:189.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/36\" class=\"nounderline abstract_t\">Miller MH, Urowitz MB, Gladman DD, Killinger DW. Systemic lupus erythematosus in males. Medicine (Baltimore) 1983; 62:327.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/37\" class=\"nounderline abstract_t\">Ward MM, Studenski S. Systemic lupus erythematosus in men: a multivariate analysis of gender differences in clinical manifestations. J Rheumatol 1990; 17:220.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/38\" class=\"nounderline abstract_t\">Prete PE, Majlessi A, Gilman S, Hamideh F. Systemic lupus erythematosus in men: a retrospective analysis in a Veterans Administration Healthcare System population. J Clin Rheumatol 2001; 7:142.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/39\" class=\"nounderline abstract_t\">Ward MM, Polisson RP. A meta-analysis of the clinical manifestations of older-onset systemic lupus erythematosus. Arthritis Rheum 1989; 32:1226.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/40\" class=\"nounderline abstract_t\">Boddaert J, Huong DL, Amoura Z, et al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 2004; 83:348.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/41\" class=\"nounderline abstract_t\">Lalani S, Pope J, de Leon F, et al. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol 2010; 37:38.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/42\" class=\"nounderline abstract_t\">Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995; 4:425.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/43\" class=\"nounderline abstract_t\">Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol 2006; 28:97.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/44\" class=\"nounderline abstract_t\">Harley JB, Kelly JA, Kaufman KM. Unraveling the genetics of systemic lupus erythematosus. Springer Semin Immunopathol 2006; 28:119.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/45\" class=\"nounderline abstract_t\">Block SR, Winfield JB, Lockshin MD, et al. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med 1975; 59:533.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/46\" class=\"nounderline abstract_t\">Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992; 35:311.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/47\" class=\"nounderline abstract_t\">Kuo CF, Grainge MJ, Valdes AM, et al. Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoimmune Diseases in Affected Families. JAMA Intern Med 2015; 175:1518.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/48\" class=\"nounderline abstract_t\">Alarc&oacute;n-Segovia D, Alarc&oacute;n-Riquelme ME, Cardiel MH, et al. Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005; 52:1138.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/49\" class=\"nounderline abstract_t\">Murashima A, Fukazawa T, Hirashima M, et al. Long term prognosis of children born to lupus patients. Ann Rheum Dis 2004; 63:50.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/50\" class=\"nounderline abstract_t\">Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358:900.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/51\" class=\"nounderline abstract_t\">Graham RR, Hom G, Ortmann W, Behrens TW. Review of recent genome-wide association scans in lupus. J Intern Med 2009; 265:680.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/52\" class=\"nounderline abstract_t\">Nath SK, Han S, Kim-Howard X, et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008; 40:152.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/53\" class=\"nounderline abstract_t\">Boackle SA. Advances in lupus genetics. Curr Opin Rheumatol 2013; 25:561.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/54\" class=\"nounderline abstract_t\">G&uuml;nther C, Meurer M, Stein A, et al. Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology 2009; 219:162.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/55\" class=\"nounderline abstract_t\">Barcellos LF, May SL, Ramsay PP, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 2009; 5:e1000696.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/56\" class=\"nounderline abstract_t\">International MHC and Autoimmunity Genetics Network, Rioux JD, Goyette P, et al. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc Natl Acad Sci U S A 2009; 106:18680.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/57\" class=\"nounderline abstract_t\">Bronson PG, Chaivorapol C, Ortmann W, et al. The genetics of type I interferon in systemic lupus erythematosus. Curr Opin Immunol 2012; 24:530.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/58\" class=\"nounderline abstract_t\">Yeung KS, Chung BH, Choufani S, et al. Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. PLoS One 2017; 12:e0169553.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/59\" class=\"nounderline abstract_t\">Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009; 182:34.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/60\" class=\"nounderline abstract_t\">Banchereau R, Hong S, Cantarel B, et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. Cell 2016; 165:551.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/61\" class=\"nounderline abstract_t\">Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58:2481.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/62\" class=\"nounderline abstract_t\">Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008; 58:2818.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/63\" class=\"nounderline abstract_t\">Deng Y, Zhao J, Sakurai D, et al. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet 2013; 9:e1003336.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/64\" class=\"nounderline abstract_t\">Bergh&ouml;fer B, Frommer T, Haley G, et al. TLR7 ligands induce higher IFN-alpha production in females. J Immunol 2006; 177:2088.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/65\" class=\"nounderline abstract_t\">Abelson AK, Delgado-Vega AM, Kozyrev SV, et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009; 68:1746.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/66\" class=\"nounderline abstract_t\">Aitman TJ, Dong R, Vyse TJ, et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006; 439:851.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/67\" class=\"nounderline abstract_t\">Yang Y, Chung EK, Wu YL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007; 80:1037.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/68\" class=\"nounderline abstract_t\">Hawn TR, Wu H, Grossman JM, et al. A stop codon polymorphism of Toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 2005; 102:10593.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/69\" class=\"nounderline abstract_t\">Orr&uacute; V, Tsai SJ, Rueda B, et al. A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet 2009; 18:569.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/70\" class=\"nounderline abstract_t\">Costenbader KH, Gay S, Alarc&oacute;n-Riquelme ME, et al. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 2012; 11:604.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/71\" class=\"nounderline abstract_t\">Altorok N, Sawalha AH. Epigenetics in the pathogenesis of systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25:569.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/72\" class=\"nounderline abstract_t\">Patel DR, Richardson BC. Dissecting complex epigenetic alterations in human lupus. Arthritis Res Ther 2013; 15:201.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/73\" class=\"nounderline abstract_t\">Shen N, Liang D, Tang Y, et al. MicroRNAs--novel regulators of systemic lupus erythematosus pathogenesis. Nat Rev Rheumatol 2012; 8:701.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/74\" class=\"nounderline abstract_t\">Sui W, Hou X, Che W, et al. The applied basic research of systemic lupus erythematosus based on the biological omics. Genes Immun 2013; 14:133.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/75\" class=\"nounderline abstract_t\">Sanchez E, Nadig A, Richardson BC, et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis 2011; 70:1752.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/76\" class=\"nounderline abstract_t\">Taylor KE, Chung SA, Graham RR, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. PLoS Genet 2011; 7:e1001311.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/77\" class=\"nounderline abstract_t\">Ceccarelli F, Perricone C, Borgiani P, et al. Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype. J Immunol Res 2015; 2015:745647.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/78\" class=\"nounderline abstract_t\">Iwamoto T, Niewold TB. Genetics of human lupus nephritis. Clin Immunol 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/79\" class=\"nounderline abstract_t\">Grammer AC, Ryals MM, Heuer SE, et al. Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis. Lupus 2016; 25:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/80\" class=\"nounderline abstract_t\">Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357:977.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/81\" class=\"nounderline abstract_t\">Taylor KE, Remmers EF, Lee AT, et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008; 4:e1000084.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/82\" class=\"nounderline abstract_t\">Svenungsson E, Gustafsson J, Leonard D, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010; 69:834.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/83\" class=\"nounderline abstract_t\">Yin H, Borghi MO, Delgado-Vega AM, et al. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009; 60:2468.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/84\" class=\"nounderline abstract_t\">Lu R, Vidal GS, Kelly JA, et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun 2009; 10:397.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/85\" class=\"nounderline abstract_t\">J&ouml;nsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 2007; 46:1417.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/86\" class=\"nounderline abstract_t\">Kyogoku C, Tsuchiya N, Wu H, et al. Association of Fcgamma receptor IIA, but not IIB and IIIA, polymorphisms with systemic lupus erythematosus: A family-based association study in Caucasians. Arthritis Rheum 2004; 50:671.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/87\" class=\"nounderline abstract_t\">Croker JA, Kimberly RP. Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17:529.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/88\" class=\"nounderline abstract_t\">Kim-Howard X, Maiti AK, Anaya JM, et al. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis 2010; 69:1329.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/89\" class=\"nounderline abstract_t\">Crisp&iacute;n JC, Hedrich CM, Tsokos GC. Gene-function studies in systemic lupus erythematosus. Nat Rev Rheumatol 2013; 9:476.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/90\" class=\"nounderline abstract_t\">Kariuki SN, Ghodke-Puranik Y, Dorschner JM, et al. Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun 2015; 16:15.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/91\" class=\"nounderline abstract_t\">McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum 2003; 48:2100.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/92\" class=\"nounderline abstract_t\">Li J, May W, McMurray RW. Pituitary hormones and systemic lupus erythematosus. Arthritis Rheum 2005; 52:3701.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/93\" class=\"nounderline abstract_t\">Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005; 142:953.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/94\" class=\"nounderline abstract_t\">Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2550.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/95\" class=\"nounderline abstract_t\">S&aacute;nchez-Guerrero J, Uribe AG, Jim&eacute;nez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005; 353:2539.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/96\" class=\"nounderline abstract_t\">S&aacute;nchez-Guerrero J, Gonz&aacute;lez-P&eacute;rez M, Durand-Carbajal M, et al. Menopause hormonal therapy in women with systemic lupus erythematosus. Arthritis Rheum 2007; 56:3070.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/97\" class=\"nounderline abstract_t\">Hughes GC, Choubey D. Modulation of autoimmune rheumatic diseases by oestrogen and progesterone. Nat Rev Rheumatol 2014; 10:740.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/98\" class=\"nounderline abstract_t\">Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol 1995; 13:217.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/99\" class=\"nounderline abstract_t\">Cohen-Solal JF, Jeganathan V, Hill L, et al. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 2008; 17:528.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/100\" class=\"nounderline abstract_t\">Cohen-Solal JF, Jeganathan V, Grimaldi CM, et al. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol 2006; 305:67.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/101\" class=\"nounderline abstract_t\">Lahita RG. Sex hormones and the immune system--Part 1. Human data. Baillieres Clin Rheumatol 1990; 4:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/102\" class=\"nounderline abstract_t\">Lee J, Shin EK, Lee SY, et al. Oestrogen up-regulates interleukin-21 production by CD4(+) T lymphocytes in patients with systemic lupus erythematosus. Immunology 2014; 142:573.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/103\" class=\"nounderline abstract_t\">Clemens LE, Siiteri PK, Stites DP. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979; 122:1978.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/104\" class=\"nounderline abstract_t\">Buskila D, Sukenik S, Shoenfeld Y. The possible role of prolactin in autoimmunity. Am J Reprod Immunol 1991; 26:118.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/105\" class=\"nounderline abstract_t\">Blanco-Favela F, Quintal-Alvarez G, Lea&ntilde;os-Miranda A. Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power. J Rheumatol 1999; 26:55.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/106\" class=\"nounderline abstract_t\">Weetman AP, Walport MJ. The association of autoimmune thyroiditis with systemic lupus erythematosus. Br J Rheumatol 1987; 26:359.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/107\" class=\"nounderline abstract_t\">Gl&uuml;ck T, Oertel M, Reber T, et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. I. The hypothalamus-autonomic nervous system axis. J Rheumatol 2000; 27:903.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/108\" class=\"nounderline abstract_t\">Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85:303.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/109\" class=\"nounderline abstract_t\">Theofilopoulos AN. The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995; 16:90.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/110\" class=\"nounderline abstract_t\">Hahn BH, Ebling F, Singh RR, et al. Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 2005; 1051:433.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/111\" class=\"nounderline abstract_t\">Elkon K. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:384.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/112\" class=\"nounderline abstract_t\">Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/113\" class=\"nounderline abstract_t\">Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/114\" class=\"nounderline abstract_t\">Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease. A problem of defective apoptosis. Arthritis Rheum 1994; 37:1415.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/115\" class=\"nounderline abstract_t\">Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005; 17:513.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/116\" class=\"nounderline abstract_t\">Mu&ntilde;oz LE, Janko C, Grossmayer GE, et al. Remnants of secondarily necrotic cells fuel inflammation in systemic lupus erythematosus. Arthritis Rheum 2009; 60:1733.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/117\" class=\"nounderline abstract_t\">Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013; 368:1528.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/118\" class=\"nounderline abstract_t\">Gerl V, Lischka A, Panne D, et al. Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. Ann Rheum Dis 2010; 69:1370.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/119\" class=\"nounderline abstract_t\">R&ouml;nnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006; 54:408.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/120\" class=\"nounderline abstract_t\">Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/121\" class=\"nounderline abstract_t\">Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3958.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/122\" class=\"nounderline abstract_t\">Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100:2610.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/123\" class=\"nounderline abstract_t\">Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2951.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/124\" class=\"nounderline abstract_t\">Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010; 19:1012.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/125\" class=\"nounderline abstract_t\">Jensen MA, Niewold TB. Interferon regulatory factors: critical mediators of human lupus. Transl Res 2015; 165:283.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/126\" class=\"nounderline abstract_t\">Delfani P, Sturfelt G, Gullstrand B, et al. Deciphering systemic lupus erythematosus-associated serum biomarkers reflecting apoptosis and disease activity. Lupus 2017; 26:373.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/127\" class=\"nounderline abstract_t\">Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38:550.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/128\" class=\"nounderline abstract_t\">Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/129\" class=\"nounderline abstract_t\">Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48:1332.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/130\" class=\"nounderline abstract_t\">Jacobi AM, Reiter K, Mackay M, et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008; 58:1762.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/131\" class=\"nounderline abstract_t\">Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178:2579.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/132\" class=\"nounderline abstract_t\">Stohl W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum 1995; 38:506.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/133\" class=\"nounderline abstract_t\">Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/134\" class=\"nounderline abstract_t\">Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990; 33:1216.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/135\" class=\"nounderline abstract_t\">Terrier B, Costedoat-Chalumeau N, Garrido M, et al. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 2012; 39:1819.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/136\" class=\"nounderline abstract_t\">Pugh-Bernard AE, Cambier JC. B cell receptor signaling in human systemic lupus erythematosus. Curr Opin Rheumatol 2006; 18:451.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/137\" class=\"nounderline abstract_t\">Gatto M, Zen M, Ghirardello A, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013; 12:523.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/138\" class=\"nounderline abstract_t\">Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther 2011; 13:207.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/139\" class=\"nounderline abstract_t\">Crisp&iacute;n JC, Kyttaris VC, Juang YT, Tsokos GC. How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 2008; 29:110.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/140\" class=\"nounderline abstract_t\">Peng SL. Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 2009; 8:179.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/141\" class=\"nounderline abstract_t\">Wu XN, Ye YX, Niu JW, et al. Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus. Sci Transl Med 2014; 6:246ra99.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/142\" class=\"nounderline abstract_t\">Mohan C, Datta SK. Lupus: key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol 1995; 77:209.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/143\" class=\"nounderline abstract_t\">Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998; 9:721.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/144\" class=\"nounderline abstract_t\">Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201:703.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/145\" class=\"nounderline abstract_t\">Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus: will the promise be fulfilled? Immunol Rev 2008; 223:156.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/146\" class=\"nounderline abstract_t\">Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/147\" class=\"nounderline abstract_t\">Navarra SV, Guzm&aacute;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/148\" class=\"nounderline abstract_t\">Steinberg AD. Insights into the basis of systemic lupus. J Autoimmun 1995; 8:771.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/149\" class=\"nounderline abstract_t\">Tsokos GC. Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation. Arthritis Rheum 2008; 58:1216.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/150\" class=\"nounderline abstract_t\">Abbud Filho M, Pavarino-Bertelli EC, Alvarenga MP, et al. Systemic lupus erythematosus and microchimerism in autoimmunity. Transplant Proc 2002; 34:2951.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/151\" class=\"nounderline abstract_t\">Dye JR, Ullal AJ, Pisetsky DS. The role of microparticles in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Scand J Immunol 2013; 78:140.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/152\" class=\"nounderline abstract_t\">L&oacute;pez P, G&oacute;mez J, Prado C, et al. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 2008; 35:1559.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/153\" class=\"nounderline abstract_t\">Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50:3596.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/154\" class=\"nounderline abstract_t\">Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008; 20:538.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/155\" class=\"nounderline abstract_t\">Goodnow CC. Immunology. Discriminating microbe from self suffers a double toll. Science 2006; 312:1606.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/156\" class=\"nounderline abstract_t\">Papadimitraki ED, Choulaki C, Koutala E, et al. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006; 54:3601.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/157\" class=\"nounderline abstract_t\">Migita K, Miyashita T, Maeda Y, et al. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007; 34:493.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/158\" class=\"nounderline abstract_t\">Nakano S, Morimoto S, Suzuki J, et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47:145.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/159\" class=\"nounderline abstract_t\">Means TK, Latz E, Hayashi F, et al. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005; 115:407.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/160\" class=\"nounderline abstract_t\">Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 2007; 19:11.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/161\" class=\"nounderline abstract_t\">Magna M, Pisetsky DS. The Role of Cell Death in the Pathogenesis of SLE: Is Pyroptosis the Missing Link? Scand J Immunol 2015; 82:218.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/162\" class=\"nounderline abstract_t\">Barnado A, Crofford LJ, Oates JC. At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol 2016; 99:265.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/163\" class=\"nounderline abstract_t\">Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/164\" class=\"nounderline abstract_t\">Li J, Xie H, Wen T, et al. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37:766.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/165\" class=\"nounderline abstract_t\">Pisetsky DS. The complex role of DNA, histones and HMGB1 in the pathogenesis of SLE. Autoimmunity 2014; 47:487.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/166\" class=\"nounderline abstract_t\">Pisetsky DS. HMGB1: a dangerous player in lupus pathogenesis. J Rheumatol 2010; 37:689.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/167\" class=\"nounderline abstract_t\">Olferiev M, Jacek E, Kirou KA, Crow MK. Novel molecular signatures in mononuclear cell populations from patients with systemic lupus erythematosus. Clin Immunol 2016; 172:34.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/168\" class=\"nounderline abstract_t\">Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 2006; 65:216.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/169\" class=\"nounderline abstract_t\">Manfredi AA, Rovere P, Galati G, et al. Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 1998; 41:205.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/170\" class=\"nounderline abstract_t\">Manfredi AA, Rovere P, Heltai S, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41:215.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/171\" class=\"nounderline abstract_t\">Charles PJ. Defective waste disposal: does it induce autoantibodies in SLE? Ann Rheum Dis 2003; 62:1.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/172\" class=\"nounderline abstract_t\">Mevorach D. Clearance of dying cells and systemic lupus erythematosus: the role of C1q and the complement system. Apoptosis 2010; 15:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/173\" class=\"nounderline abstract_t\">Bijl M, Reefman E, Horst G, et al. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006; 65:57.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/174\" class=\"nounderline abstract_t\">Munoz LE, Gaipl US, Franz S, et al. SLE--a disease of clearance deficiency? Rheumatology (Oxford) 2005; 44:1101.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/175\" class=\"nounderline abstract_t\">Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997; 185:843.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/176\" class=\"nounderline abstract_t\">Rosen A, Casciola-Rosen L. Autoantigens in systemic autoimmunity: critical partner in pathogenesis. J Intern Med 2009; 265:625.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/177\" class=\"nounderline abstract_t\">Putterman C, Furie R, Ramsey-Goldman R, et al. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med 2014; 1:e000056.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/178\" class=\"nounderline abstract_t\">Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005; 202:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/179\" class=\"nounderline abstract_t\">Mamula MJ. Lupus autoimmunity: from peptides to particles. Immunol Rev 1995; 144:301.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/180\" class=\"nounderline abstract_t\">Tsokos GC, Kovacs B, Sfikakis PP, et al. Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:600.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/181\" class=\"nounderline abstract_t\">Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med 1999; 5:694.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/182\" class=\"nounderline abstract_t\">Mamula MJ, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994; 152:1453.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/183\" class=\"nounderline abstract_t\">Wucherpfennig KW, Strominger JL. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J Exp Med 1995; 181:1597.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/184\" class=\"nounderline abstract_t\">Kyttaris VC, Juang YT, Tsokos GC. Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol 2005; 17:518.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/185\" class=\"nounderline abstract_t\">Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/186\" class=\"nounderline abstract_t\">Chabre H, Amoura Z, Piette JC, et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38:1485.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/187\" class=\"nounderline abstract_t\">Pisetsky DS. Autoantibodies and their significance. Curr Opin Rheumatol 1993; 5:549.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/188\" class=\"nounderline abstract_t\">Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 1997; 40:1374.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/189\" class=\"nounderline abstract_t\">Singh RR, Ebling FM, Sercarz EE, Hahn BH. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J Clin Invest 1995; 96:2990.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/190\" class=\"nounderline abstract_t\">Shoenfeld Y. Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J 1994; 8:1296.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/191\" class=\"nounderline abstract_t\">Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007; 56:2344.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/192\" class=\"nounderline abstract_t\">Blomberg J, Nived O, Pipkorn R, et al. Increased antiretroviral antibody reactivity in sera from a defined population of patients with systemic lupus erythematosus. Correlation with autoantibodies and clinical manifestations. Arthritis Rheum 1994; 37:57.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/193\" class=\"nounderline abstract_t\">Cooper GS, Dooley MA, Treadwell EL, et al. Risk factors for development of systemic lupus erythematosus: allergies, infections, and family history. J Clin Epidemiol 2002; 55:982.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/194\" class=\"nounderline abstract_t\">Via CS, Handwerger BS. B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993; 5:570.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/195\" class=\"nounderline abstract_t\">James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997; 100:3019.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/196\" class=\"nounderline abstract_t\">James JA, Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol 2012; 24:383.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/197\" class=\"nounderline abstract_t\">Sekigawa I, Kaneko H, Hishikawa T, et al. HIV infection and SLE: their pathogenic relationship. Clin Exp Rheumatol 1998; 16:175.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/198\" class=\"nounderline abstract_t\">Perl A, Fernandez D, Telarico T, Phillips PE. Endogenous retroviral pathogenesis in lupus. Curr Opin Rheumatol 2010; 22:483.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/199\" class=\"nounderline abstract_t\">Lehmann P, H&ouml;lzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/200\" class=\"nounderline abstract_t\">Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/201\" class=\"nounderline abstract_t\">Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996; 97:2866.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/202\" class=\"nounderline abstract_t\">Ghaussy NO, Sibbitt WL Jr, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001; 28:2449.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/203\" class=\"nounderline abstract_t\">Parks CG, Cooper GS, Nylander-French LA, et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: a population-based, case-control study in the southeastern United States. Arthritis Rheum 2002; 46:1840.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/204\" class=\"nounderline abstract_t\">Parks CG, Cooper GS. Occupational exposures and risk of systemic lupus erythematosus: a review of the evidence and exposure assessment methods in population- and clinic-based studies. Lupus 2006; 15:728.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/205\" class=\"nounderline abstract_t\">Freemer MM, King TE Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 2006; 65:581.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/206\" class=\"nounderline abstract_t\">Finckh A, Cooper GS, Chibnik LB, et al. Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis Rheum 2006; 54:3648.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/207\" class=\"nounderline abstract_t\">Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004; 50:849.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/208\" class=\"nounderline abstract_t\">Chiou SH, Lan JL, Lin SL, et al. Pet dogs owned by lupus patients are at a higher risk of developing lupus. Lupus 2004; 13:442.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/209\" class=\"nounderline abstract_t\">Wang J, Kay AB, Fletcher J, et al. Alcohol consumption is not protective for systemic lupus erythematosus. Ann Rheum Dis 2009; 68:345.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/210\" class=\"nounderline abstract_t\">Wang J, Pan HF, Ye DQ, et al. Moderate alcohol drinking might be protective for systemic lupus erythematosus: a systematic review and meta-analysis. Clin Rheumatol 2008; 27:1557.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/211\" class=\"nounderline abstract_t\">Vlahakos DV, Foster MH, Adams S, et al. Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites. Kidney Int 1992; 41:1690.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/212\" class=\"nounderline abstract_t\">D'Andrea DM, Coupaye-Gerard B, Kleyman TR, et al. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996; 49:1214.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/213\" class=\"nounderline abstract_t\">Lehrnbecher T, Foster CB, Zhu S, et al. Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fcgamma receptor polymorphisms in control and disease populations. Blood 1999; 94:4220.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/214\" class=\"nounderline abstract_t\">Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968; 161:904.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/215\" class=\"nounderline abstract_t\">Lewis EJ, Busch GJ, Schur PH. Gamma G globulin subgroup composition of the glomerular deposits in human renal diseases. J Clin Invest 1970; 49:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/216\" class=\"nounderline abstract_t\">Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol 1990; 9:100.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/217\" class=\"nounderline abstract_t\">Davies KA, Peters AM, Beynon HL, Walport MJ. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J Clin Invest 1992; 90:2075.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/218\" class=\"nounderline abstract_t\">Termaat RM, Assmann KJ, Dijkman HB, et al. Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 1992; 42:1363.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/219\" class=\"nounderline abstract_t\">Schmiedeke TM, St&ouml;ckl FW, Weber R, et al. Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med 1989; 169:1879.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/220\" class=\"nounderline abstract_t\">Li QZ, Xie C, Wu T, et al. Identification of autoantibody clusters that best predict lupus disease activity using glomerular proteome arrays. J Clin Invest 2005; 115:3428.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/221\" class=\"nounderline abstract_t\">Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:3623.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/222\" class=\"nounderline abstract_t\">Fries JW, Mendrick DL, Rennke HG. Determinants of immune complex-mediated glomerulonephritis. Kidney Int 1988; 34:333.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/223\" class=\"nounderline abstract_t\">Schiffer L, Bethunaickan R, Ramanujam M, et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008; 180:1938.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/224\" class=\"nounderline abstract_t\">Iwata Y, Bostr&ouml;m EA, Menke J, et al. Aberrant macrophages mediate defective kidney repair that triggers nephritis in lupus-susceptible mice. J Immunol 2012; 188:4568.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/225\" class=\"nounderline abstract_t\">Li JS, Liu MF, Lei HY. Characterization of anti-endothelial cell antibodies in the patients with systemic lupus erythematosus: a potential marker for disease activity. Clin Immunol Immunopathol 1996; 79:211.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/226\" class=\"nounderline abstract_t\">Reichlin M. Cell injury mediated by autoantibodies to intracellular antigens. Clin Immunol Immunopathol 1995; 76:215.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/227\" class=\"nounderline abstract_t\">McClain MT, Arbuckle MR, Heinlen LD, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004; 50:1226.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/228\" class=\"nounderline abstract_t\">Norris DA. Pathomechanisms of photosensitive lupus erythematosus. J Invest Dermatol 1993; 100:58S.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/229\" class=\"nounderline abstract_t\">Golan TD, Elkon KB, Gharavi AE, Krueger JG. Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation. J Clin Invest 1992; 90:1067.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/230\" class=\"nounderline abstract_t\">Reefman E, Kuiper H, Jonkman MF, et al. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) 2006; 45:538.</a></li><li><a href=\"https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-systemic-lupus-erythematosus/abstract/231\" class=\"nounderline abstract_t\">Marion TN, Postlethwaite AE. Chance, genetics, and the heterogeneity of disease and pathogenesis in systemic lupus erythematosus. Semin Immunopathol 2014; 36:495.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4669 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H443498\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">EPIDEMIOLOGY</a><ul><li><a href=\"#H2\" id=\"outline-link-H2\">Geographic and racial distribution</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Gender</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Age at onset</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Factors affecting disease outcome</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">ETIOLOGY</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Genetic factors</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Hormonal factors</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Immune abnormalities</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Environmental factors</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">PATHOGENESIS OF CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H12\" id=\"outline-link-H12\">Renal disease</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Cell-surface antibodies</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Antiphospholipid antibodies</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Skin lesions</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H16\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H443498\" id=\"outline-link-H443498\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=apoptosis-and-autoimmune-disease\" class=\"medical medical_review\">Apoptosis and autoimmune disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-significance-of-antinuclear-antibody-staining-patterns-and-associated-autoantibodies\" class=\"medical medical_review\">Clinical significance of antinuclear antibody staining patterns and associated autoantibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-classification-of-renal-disease-in-systemic-lupus-erythematosus\" class=\"medical medical_review\">Diagnosis and classification of renal disease in systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hematologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Hematologic manifestations of systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=human-leukocyte-antigens-hla-a-roadmap\" class=\"medical medical_review\">Human leukocyte antigens (HLA): A roadmap</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurologic-manifestations-of-systemic-lupus-erythematosus\" class=\"medical medical_review\">Neurologic manifestations of systemic lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=normal-b-and-t-lymphocyte-development\" class=\"medical medical_review\">Normal B and T lymphocyte development</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">Overview of cutaneous lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-of-antiphospholipid-syndrome\" class=\"medical medical_review\">Pathogenesis of antiphospholipid syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=systemic-lupus-erythematosus-sle-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Systemic lupus erythematosus (SLE) (Beyond the Basics)</a></li></ul></div></div>","javascript":null}